Financial Performance - Fourth-quarter 2024 total net sales were $667.5 million, a decrease of 2.0% compared to $681.2 million in Q4 2023[4] - Full-year 2024 reported net sales decreased 3.9% to $2,566.5 million compared to $2,671.2 million in 2023[12] - Bio-Rad reported net sales of $667.5 million for Q4 2024, a decrease of 2.3% from $681.2 million in Q4 2023[37] - For the full year 2024, Bio-Rad's revenues totaled $2.566 billion, down from $2.671 billion in 2023, marking a decline of 3.9%[37] Segment Performance - Life Science segment net sales for Q4 2024 were $275.0 million, a decline of 5.5% year-over-year, driven by weakness in biotech and biopharma markets[5] - Clinical Diagnostics segment net sales for Q4 2024 were $392.5 million, an increase of 0.9% compared to Q4 2023, primarily due to increased demand for quality control and blood typing products[6] Profitability Metrics - Full-year 2024 gross margin was 53.7%, compared to 53.4% in 2023[14] - Non-GAAP gross margin for full-year 2024 was 55.0%, compared to 54.2% in 2023[17] - GAAP gross profit for Q4 2024 was $342.0 million, representing 51.2% of revenue, compared to $366.3 million and 53.8% in Q4 2023[45] - Non-GAAP gross profit for the year ended December 31, 2024, was $1,411.6 million, or 55.0% of revenue, compared to $1,448.3 million and 54.2% in 2023[45] Income and Loss - The company experienced a net loss of $715.8 million in Q4 2024, compared to a net income of $349.7 million in Q4 2023, resulting in a basic loss per share of $25.57[37] - GAAP net income for the period was $(715.8) million, a decrease of 107.2% compared to the previous year[48] - The company reported a significant loss of $(1,844.2) million in GAAP net income for the year, a decrease of 71.9%[48] - Non-GAAP net income was $81.2 million, representing a 12.2% margin, while the previous year's figure was $89.3 million with a 13.1% margin[48] Expenses - Research and development expenses increased to $79.6 million in Q4 2024, up from $63.9 million in Q4 2023, reflecting a growth of 24.5%[37] - GAAP research and development expense for Q4 2024 was $79.6 million, up from $63.9 million in Q4 2023[46] - Non-GAAP research and development expense for the year ended December 31, 2024, was $281.8 million, compared to $254.8 million in 2023[46] - GAAP selling, general and administrative expense for Q4 2024 was $204.0 million, slightly down from $207.1 million in Q4 2023[45] - Non-GAAP selling, general and administrative expense for the year ended December 31, 2024, was $798.5 million, compared to $814.6 million in 2023[45] Cash Flow and Assets - Cash and cash equivalents at the end of 2024 were $488.1 million, an increase from $403.8 million at the end of 2023[40] - Total assets decreased to $9.364 billion in 2024 from $12.299 billion in 2023, a decline of 23.6%[40] - The company reported cash provided by operating activities of $455.2 million for the year ended December 31, 2024, compared to $374.9 million in 2023, an increase of 21.4%[42] Future Outlook - The company expects non-GAAP, currency-neutral revenue growth of approximately 1.5% to 3.5% for full-year 2025[20] - The company expects continued focus on market expansion and new product development in the upcoming quarters[46] - The anticipated acquisition of Stilla Technologies is expected to further Bio-Rad's planned transformation and commercial excellence[34] - Forecasted non-GAAP operating margin for 2025 excludes 87 basis points related to amortization of purchased intangibles[51] - The company noted that future financial expectations are subject to significant uncertainty and cannot be reasonably predicted[51] Tax and Liabilities - The effective tax rate for full-year 2024 was 21.3%, down from 25.0% in 2023[16] - Bio-Rad's total liabilities decreased to $2.794 billion in 2024 from $3.558 billion in 2023, a reduction of 21.5%[40] Acquisition and Restructuring Costs - Bio-Rad announced the intent to acquire Stilla Technologies, a digital PCR developer, expected to close by the end of Q3 2025[22] - The company incurred acquisition-related costs of $11.7 million and restructuring costs of $14.7 million during the reporting period[48]

Company Overview - Bio-Rad Laboratories (BIO) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended December 2024 [1] - The earnings report is scheduled for release on February 13, 2025, and could influence the stock price depending on whether the results meet or exceed expectations [2] Earnings Estimates - The Zacks Consensus Estimate predicts quarterly earnings of $2.92 per share, reflecting a year-over-year decrease of 5.8% [3] - Expected revenues are $674.71 million, which is a 1% decline from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 0.22% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10] - Bio-Rad's Earnings ESP is currently at -2.06%, suggesting a lower Most Accurate Estimate compared to the Zacks Consensus Estimate [11] Earnings Surprise History - In the last reported quarter, Bio-Rad exceeded expectations by delivering earnings of $2.01 per share against an expected $1.28, resulting in a surprise of +57.03% [12] - Over the past four quarters, the company has consistently beaten consensus EPS estimates [13] Market Sentiment - Despite the historical ability to beat estimates, the current combination of a negative Earnings ESP and a Zacks Rank of 2 (Buy) complicates predictions for the upcoming earnings report [11][16] - The company does not appear to be a compelling candidate for an earnings beat based on current indicators, but other factors should also be considered by investors [16]

Company Overview - Bio-Rad Laboratories (BIO) is part of the Medical sector, which includes 1013 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The Zacks Rank for Bio-Rad Laboratories is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - The Zacks Consensus Estimate for Bio-Rad's full-year earnings has increased by 0.7% over the past quarter, reflecting stronger analyst sentiment and an improving earnings outlook [4] - Year-to-date, Bio-Rad has gained approximately 7.5%, outperforming the average return of 5.7% for Medical companies [4] - In the Medical - Products industry, which includes 83 stocks, Bio-Rad is ranked 140 and has slightly underperformed its industry, which has gained an average of 9.8% this year [6] Comparative Analysis - Certara, Inc. (CERT) is another Medical stock that has outperformed the sector with a year-to-date return of 31.3% and a Zacks Rank of 2 (Buy) [5] - Certara belongs to the Medical - Biomedical and Genetics industry, which is ranked 68 and has increased by 4.5% this year [6] Investment Outlook - Both Bio-Rad Laboratories and Certara, Inc. are highlighted as stocks to watch for investors interested in the Medical sector due to their solid performance [7]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company will provide a corporate overview and participate in one-on-one meetings with registered investors during the conference [2][3] - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets [5] - Key product candidates include PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a plant cell-expressed long-action DNase I for NETs-related diseases [5]

CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive o ...

Core Insights - Bio-Rad Laboratories, Inc. is experiencing solid momentum in its QX600 Droplet Digital PCR (ddPCR) platform, which is expected to drive growth in upcoming quarters [1] - The clinical diagnostics business is seeing increased demand for quality control products, contributing to overall growth [1] - The company is focusing on international expansion, which is anticipated to yield positive results [1] - However, there are concerns regarding a soft Biopharma segment and macroeconomic pressures affecting Bio-Rad's margins [1] Group 1: Business Performance - Bio-Rad's shares have increased by 13.3% over the past year, outperforming the industry growth of 9.3% and the S&P 500's rise of 25.6% [2] - The company has a market capitalization of $9.57 billion and has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 30.45% [2] - The ddPCR franchise grew in mid-single digits in Q3 2024, supported by additional IP-related royalties and successful market penetration in oncology and cell and gene therapy [5] Group 2: Clinical Diagnostics - The clinical diagnostics segment is experiencing growth, particularly in the diabetes franchise and improvements in immunohematology and quality control businesses [6] - The launch of the IH-500 next instrument aims to enhance system functionality and security, contributing to the competitiveness of the transfusion medicine portfolio [6] - Increased demand for quality control products and favorable comparisons in immunology products have driven growth in the clinical diagnostics group [6] Group 3: International Operations - Bio-Rad operates in over 35 countries outside the United States, with significant international distribution channels [7] - Despite soft market conditions in the Asia-Pacific region, the company remains optimistic about gradual improvements into 2025 [7] - Challenges in key European markets, particularly in Germany and the UK, are expected to be offset by modest improvements in funding outlooks in France and other countries [9] Group 4: Challenges - The Biopharma segment is facing softness, particularly among smaller companies, due to funding constraints in the broader pharmaceutical industry [10] - Demand for process chromatography resins and life science research products has decreased, reflecting an ongoing destocking trend [10] - Bio-Rad's margins are under pressure from inflationary trends, including rising raw material costs, logistics expenses, and higher employee-related costs [11] Group 5: Financial Estimates - The Zacks Consensus Estimate for Bio-Rad's 2024 earnings per share (EPS) has increased by 0.4% to $10.33 in the past 30 days [12] - The estimated revenue for 2024 is projected at $2.57 billion, indicating a 3.7% decline from the previous year [12]

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including ...

Core Insights - Bio-Techne Corporation has announced a partnership with MedSanTek to distribute its brands in Turkey, enhancing its market presence in the region [1][3] - MedSanTek is recognized as a leading distributor in in vitro diagnostics and research products, serving Turkey and Azerbaijan, and is known for its high-quality solutions in various scientific fields [2][3] - The partnership aims to leverage MedSanTek's local expertise and Bio-Techne's innovative product portfolio to advance scientific research and healthcare in Turkey and Azerbaijan [3] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [4] - The company employs around 3,100 people worldwide and offers a vast portfolio of products that assist in scientific investigations and drug discovery [4]

Core Insights - BIO-key International, Inc. has entered into an agreement with Fiber Food Systems, Inc. to enhance security and operational efficiency in the food service sector through the integration of identity and access management (IAM) solutions [1][2][3] Company Overview - BIO-key specializes in workforce and customer identity and access management solutions, focusing on Identity-Bound Biometrics for secure authentication experiences [1][8] - Fiber Food Systems is dedicated to global food security and innovation in food technology, producing high-demand consumer packaged goods and plant-based proteins [1][9] Transaction Details - BIO-key acquired 5,000,000 shares of Boumarang, Inc. from Fiber in exchange for 595,000 shares of BIO-key, representing 19% of BIO-key's issued shares, strengthening its balance sheet with an additional $5 million in net assets [1] Strategic Collaboration - The partnership aims to combine BIO-key's IAM expertise with Fiber's food technology, enhancing security and streamlining access in high-traffic environments such as schools and universities [2][3] - BIO-key's PortalGuard IAM platform supports over 35 million users with phoneless, tokenless, and passwordless access options, which will be integrated into Fiber's food service operations [2][8] Innovation and Growth Opportunities - The collaboration is expected to improve operational efficiency in time-sensitive food service environments by deploying biometric authentication [4] - BIO-key's scalable IAM solutions will allow Fiber to implement tailored security measures across its expanding food tech and distribution network [5] - The partnership reflects a commitment to innovation in the food tech sector, setting a benchmark for safety and efficiency in food service technology [6] Leadership Statements - The CEO of BIO-key emphasized the importance of delivering secure IAM solutions to industries requiring seamless access, particularly in food services [7] - The Executive Chairperson of Fiber highlighted the alignment of their mission with BIO-key's technology to transform the food tech industry [7]

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...